FDA Classifies STI Detection Device for Quicker Patient Access
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying devices that detect DNA from non-viral germs causing sexually transmitted infections (STIs) and their resistance markers as Class II, meaning they have special safety rules but fewer hurdles than the strictest category. This change helps companies bring these important tests to patients faster and safer, starting May 9, 2025. Labs, device makers, and patients will all benefit from quicker access to innovative STI testing without extra red tape.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Clinical Study and Documentation Requirements
The special controls require detailed design verification and validation, including analytical studies and clinical study results with prospective samples for each claimed specimen type, a predefined statistical analysis plan, and documentation of software impacts (21 CFR 866.3393(b)(4) and (3)(iii)-(iv)).
Faster Access to STI DNA Tests
The FDA officially classifies tests that detect DNA from non-viral germs causing sexually transmitted infections and their resistance markers as Class II with special controls, effective May 9, 2025 (classification was applicable January 23, 2019). The agency says this classification reduces regulatory burdens and will help patients get innovative STI tests more quickly.
Enables 510(k) Predicate Use
When FDA classifies this device type via De Novo, that device can serve as a predicate for future devices, allowing other sponsors to use the less-burdensome 510(k) process instead of premarket approval. The final order codifies the device type into 21 CFR 866.3393 and notes the device is subject to premarket notification requirements under section 510(k) of the FD&C Act.
Sample-Collection Devices Must Be Cleared
Any sample collection device used with these tests must be FDA-cleared, -approved, or -classified as 510(k) exempt for the claimed specimen types, or must be cleared in the premarket submission as part of the test. This requirement is set out in the special controls at 21 CFR 866.3393(b)(2).
Labeling Must Warn About Test Limits
The device labeling must include statements that a negative test does not rule out infection, results should be interpreted with other clinical data, and detection of resistance markers does not prove antibiotic susceptibility. The special controls (21 CFR 866.3393(b)(3)(iv) and (b)(3)(v)) spell out these limiting statements for users and clinicians.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2025-08148, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Voriconazole Test System
The FDA is officially classifying the voriconazole test system as a Class II device with special safety rules, making it safer and easier to get to patients. This change lowers regulatory hurdles, speeding up access to this important medical test without extra costs. The new classification is effective May 9, 2025, benefiting device makers and patients alike.
Next: 2025-08150, Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microbial Nucleic Acids by Fluorescence In Situ Hybridization in Clinical Specimens
The FDA is officially classifying a special device that detects and identifies tiny germs in patient samples using a cool glowing technique called FISH as a Class II device, meaning it’s safe and effective with some special rules. This change helps get these innovative tools to patients faster by cutting down red tape. The new rules took effect on May 9, 2025, and mainly affect companies making or using these devices in healthcare.